STAT+: Could sickle cell someday be treated not with CRISPR, but with a pill?
Two gene therapies were approved for sickle cell disease last week, but for many researchers…
Category: ASH
STAT+: A targeted therapy shows it can offer a ‘last, great chance’ for some acute leukemia patients
SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration…
STAT+: Bone marrow transplant advance could widen use of this less buzzy cure for sickle cell disease
SAN DIEGO — The sickle cell community has for the past few days been buzzing…
STAT+: Late-stage trial supports broader use of Darzalex, blockbuster J&J multiple myeloma drug
SAN DIEGO — Johnson & Johnson’s multiple myeloma therapy, Darzalex, is already a blockbuster. Now…
STAT+: Historic approval of sickle cell gene therapies met with cautious optimism by experts at ASH
SAN DIEGO — News of the Food and Drug Administration’s historic approval of the first…
STAT+: CAR-T, recently used in a lupus patient, helps other autoimmune patients, too, in small study
SAN DIEGO — When the first lupus patient received CAR-T therapy, researchers watched in amazement as…
STAT+: Was CAR-T therapy a bystander or driver of lymphoma? Researchers examine first published case
SAN DIEGO — Researchers on Saturday presented an unusual case of a T cell lymphoma…
STAT+: Divergent results from Agios, Forma trials for their sickle cell disease drugs
Two drug makers — Forma Therapeutics and Agios Pharmaceuticals — are each developing their own…
STAT+: With new data and a storied history, Eli Lilly’s blood cancer pill is looking stronger
Three years ago, the biotech firm Loxo Oncology purchased a promising blood cancer pill for…
STAT+: Constellation’s blood cancer drug shows greater benefit, easing concerns about its future
More patients and an improved response rate might once again shift the sentiment on Constellation…
STAT+: J&J’s CAR-T drug maintains strong efficacy in myeloma, shaded by neurotoxicity
More than three-quarters of the multiple myeloma patients treated with an experimental CAR-T therapy from…
STAT+: Genetically targeted drug from Kura Oncology induces remissions in adult leukemia patients
Kura Oncology presented early clinical trial results Saturday showing for the first time that its…
Preliminary but ‘nothing short of great.’ New data on CRISPR treatment for blood diseases suggest cure is possible
Ten patients treated with a CRISPR-based gene-editing therapy for the inherited blood disorders sickle cell…